| Title: |
GLP-1 Receptor Agonists in Overweight and Obese Individuals With Type 1 Diabetes Using an Automated Insulin Delivery Device:A Real-World Study |
| Authors: |
Holmager, Pernille; Christensen, Merete Bechmann; Nørgaard, Kirsten; Schmidt, Signe |
| Source: |
Holmager , P , Christensen , M B , Nørgaard , K & Schmidt , S 2025 , ' GLP-1 Receptor Agonists in Overweight and Obese Individuals With Type 1 Diabetes Using an Automated Insulin Delivery Device : A Real-World Study ' , Journal of Diabetes Science and Technology , vol. 19 , no. 2 , pp. 286-291 . https://doi.org/10.1177/19322968241289438 |
| Publication Year: |
2025 |
| Collection: |
University of Copenhagen: Research / Forskning ved Københavns Universitet |
| Subject Terms: |
automated insulin delivery; body weight; glucagon-like peptide-1 receptor agonists; HbA1c; type 1 diabetes |
| Description: |
Introduction: Automated insulin delivery (AID) systems have improved glycemic control in individuals with type 1 diabetes (T1D) but overweight and increased cardiovascular risk remain a challenge. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with improved cardiometabolic profile but are currently not approved for the treatment of T1D. Material and methods: Individuals with T1D at Steno Diabetes Center Copenhagen, Denmark, treated with AID and off-label GLP-1 RA for at least six months between January 2017 and May 2024 were included in a retrospective chart review study. Results: Nineteen individuals with (median [range]) age 42 (24-60) years were included. At GLP-1 RA initiation, hemoglobin A1c (HbA1c) was 7.3% (6.1%-8.7%), HbA1c 56 (43-72) mmol/mol, body weight 91.5 (78.0-115.0) kg, and body mass index 35.4 (27.0-42.0) kg/m2. Time in range was 74% (29%-82%), time above range 25% (18%-71%) while time below range was 1% (0%-5%). After six months of treatment, body weight changed −11% (−22% to −3%; P =.001) and total daily insulin dose changed −15.1 (−32.5 to −8.2) IU (P =.004). There were no significant changes in HbA1c or other glucose measures. One person developed ketoacidosis caused by infusion set failure, but none reported severe hypoglycemia. Conclusion: Glucagon-like peptide-1 receptor agonist as add-on therapy for six months in individuals with obesity and AID-treated T1D led to considerable weight loss and a reduction in insulin dose. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1177/19322968241289438 |
| Availability: |
https://researchprofiles.ku.dk/da/publications/7495a640-c0e2-4395-b445-170dd659a917; https://doi.org/10.1177/19322968241289438; https://pmc.ncbi.nlm.nih.gov/articles/PMC11571627/pdf/10.1177_19322968241289438.pdf |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.233C9B06 |
| Database: |
BASE |